Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia

Hematological Oncology

Volumn 25, Issue 2, 2007, Pages 84-89

  Ferrara, Felicetto ^a,b   Viola, Assunta ^a   Copia, Carolina ^a   Falco, Claudio ^a   D'Elia, Rossella ^a   Tambaro, Francesco Paolo ^a   Correale, Pasqualino ^a   D'Amico, Maria Rosaria ^a   Vicari, Laura ^a   Palmieri, Salvatore ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Acute myeloid leukemia; Age; Mobilization; Stem cells

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AGING; APHERESIS; ARTICLE; CD34 SELECTION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE SEQUENCE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 34250865646     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.810     Document Type: Article

References (41)

1. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439-449.
2. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
3. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
4. de la Rubia J, Saavedra S, Sanz GF, et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21-25.
5. Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001; 27: 1189-1195.
6. Jantunen E, Itala M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 37: 367-372.
7. Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005; 46: 1575-1579.
8. Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000; 110: 887-893.
9. Ferrara F, Venditti A, Carella AM, Jr, et al. Autologous stem cell transplantation for patients with acute myeloid leukaemia aged over 60 years. Eur J Haematol 2002; 69: 200-204.
10. Oriol A, Ribera JM, Esteve J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 2004; 89: 791-800.
11. Lashkari A, Lowe T, Collisson E, et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients >or=60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12: 466-471.
12. Cottler-Fox M, Lapidot T. Mobilizing the older patient with myeloma. Blood Rev 2006; 20: 43-50.
13. Fietz T, Rieger K, Dimeo F, Blau IW, Thiel E, Knauf WU. Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly? J Clin Apheresis 2004; 19: 202-207.
14. + cells in multiple myeloma. Ann Hematol 2001; 80: 592-597.
15. Ikeda K, Kozuka T, Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apheresis Sci 2004; 31: 245-259.
16. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981.
17. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005; 89: 229-235.
18. Lysak D, Koza V, Jindra P. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 2005; 33: 275-283.
19. + acute leukemia of myeloid and T lymphoid lineage. Leukemia 1996; 10: 1990-1992.
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Int Med 1985; 105: 620-625.
21. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
22. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
23. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukaemia. Haematologica 2005; 90: 776-784.
24. Ferrara F, Palmieri S, Annunziata M, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukaemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573-576.
25. Ferrara F, Palmieri S, De Simone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234-241.
26. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
27. Mathews V, DiPersio JF. Stem cell transplantation in acute myelogenous leukemia in first remission: what are the options? Curr Hematol Rep 2004; 3: 235-241.
28. Breems DA, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005; 128: 59-65.
29. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organi zation for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. New Engl J Med 1995; 332: 217-223.
30. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Engl J Med 1998; 339: 1649-1656.
31. Burnett AK, Goldstone AH, Stevens RM, et al. Randomized comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700-708.
32. Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96: 38-45.
33. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 2004; 89: 998-1008.
34. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 65-75.
35. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
36. Van Zant G, Liang Y. 2003; The role of stem cells in aging. Exp Hematol 2003; 31: 659-672.
37. de Witte T, Brand R, van Biezen A, et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 2006; 91: 750-756.
38. Visani G, Lemoli RM, Tosi P, et al. Fludarabine containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-779.
39. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003; 44: 391-409.
40. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-365.
41. Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002; 68: 203-209.